# US 2016/0252532 A1 · pH-Biosensors Based on Compounds Produced From Pyruvic Acid For Magnetic Resonance Imaging and Spectroscopy and Their Uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252532 A1
- Document ID: US20160252532A1
- Status: Published application
- Kind: A1
- Application number: 15/028,219
- Filed: 2014-10-15
- Published: 2016-09-01
- Earliest claimed: 2013-10-15
- Assignees: Technische Universität München
- Applicants: Technische UniversitäT MüNchen
- Inventors: Franz SCHILLING; Steffen GLASER; Stephan DÜWEL; Malte GERSCH
- Web page: https://patentgrep.com/patent/US20160252532A1

## CPC

- G01N 33/84: involving inorganic compounds or pH
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/14539: {for measuring pH}
- A61B 5/7278: {Artificial waveform generation or derivation, e.g. synthesizing signals from measured signals}
- A61K 49/10: Organic compounds
- G01N 24/08: by using nuclear magnetic resonance (G01N24/12 takes precedence)
- G01N 24/088: {Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics}
- G01R 33/281: {Means for the use of in vitro contrast agents (G01R33/282 takes precedence; involving use of a contrast agent in MR imaging G01R33/5601; in vivo contrast agents A61K49/0002)}
- G01R 33/465: applied to biological material, e.g. in vitro testing
- G01R 33/5601: {involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent}
- A61B 5/08: Measuring devices for evaluating the respiratory organs
- A61B 2576/02: specially adapted for a particular organ or body part
- G01N 2458/15: Non-radioactive isotope labels, e.g. for detection by mass spectrometry
- G16H 30/40: for processing medical images, e.g. editing
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to the use of compounds with at least one pH-sensitive chemical shift for determining pH and/or measuring pH changes in magnetic resonance. More specifically, the present invention is related to compounds with at least one pH-sensitive chemical shift, such compound being selected from pyruvic acid and its metabolites, compounds produced from pyruvic acid after interaction with acid, and compounds comprising at least one enolic group whose pKa value is lowered through effects of at least one neighboring group into a physiological and/or pathological pH-range, and wherein the compound exhibits at least one pH-sensitive chemical shift in an NMR spectrum. The present invention further relates to biosensors comprising at least one of the compounds. The present invention is furthermore related to in vitro and in vivo methods for determining pH and/or measuring pH changes using the compounds or biosensors. The present invention also relates to methods of diagnosing and/or monitoring treatment of a disease causing changes in pH wherein the compounds or biosensors are applied. The present invention also relates to use of the compounds or biosensors in quality control of food or in the examination of plants and organisms.

## Claims

### Claim 1

A method for determining pH and/or measuring pH changes, wherein said method comprises contacting a sample, whose pH and/or pH change is to be measured, with a compound having at least one pH-sensitive chemical shift,
wherein the compound is selected from pyruvic acid and its metabolites, compounds produced from pyruvic acid after interaction with acid, and compounds comprising at least one enolic group whose pKa value is lowered through effects of at least one neighboring group into a physiological and/or pathological pH-range.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is 13C-labeled and exhibits at least one pH-sensitive 13C chemical shift,
and/or wherein the at least one pH-sensitive chemical shift is pH-sensitive in a physiological and/or pathological pH range,
and/or wherein the compound furthermore exhibits at least one pH-insensitive 13C chemical shift.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is selected from
zymonic acid;
diethyl oxaloacetic acid;
(Z)-4-methyl-2-oxopent-3-enedioic acid (OMPD);
pyruvic acid and its metabolites,
wherein bicarbonate, acetic acid and acetate are not encompassed as metabolites of pyruvic acid;
analogs of zymonic acid;
analogs of OMPD,
and their hydrates, salts, solutions, and stereoisomers.

### Claim 4 (depends on 3)

The method of claim 3, wherein the analog of zymonic acid or OMPD is selected from
wherein X is selected from CR6R7, O, NR6, S, and wherein each of R1 to R7 is, at each occurrence, independently selected from H, alkyl, halogen, CN, methoxy, carboxy, and aryl.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound is hyperpolarized,
and/or wherein the compound has a pka value in a physiological and/or pathological pH range, and/or the carbon(s) belonging to the pH-sensitive chemical shift(s) of the compound exhibit(s) a long longitudinal relaxation time T1.

### Claim 6 (depends on 1)

A biosensor for determining pH and/or measuring pH changes, comprising
at least one compound with at least one pH-sensitive chemical shift as defined in claim 1,
optionally, a reference compound,
optionally, one or more pharmaceutically acceptable carriers and/or excipients.

### Claim 7 (depends on 6)

The biosensor of claim 6 comprising
(i) a pH sensitive fragment
comprising at least one compound having at least one pH-sensitive chemical shift,
wherein the compound is selected from pyruvic acid and its metabolites, compounds produced from pyruvic acid after interaction with acid, and compounds comprising at least one enolic group whose pKa value is lowered through effects of at least one neighboring group into a physiological and/or pathological pH-range,
coupled, optionally via a linker, to (ii),
(ii) a modulator fragment,
that controls subcellular localization, cellular uptake, pharmacokinetic properties and/or specific binding to target cells and/or tissue.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 1)

A method selected from:
A) an in-vitro method for determining pH and/or measuring pH changes, comprising the steps of
(i) providing a sample,
(ii) contacting the sample with a compound having at least one pH-sensitive chemical shift of claim 1, and
(iii) performing magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS) and thereby determining the pH or pH changes of, or in, the sample by obtaining a chemical shift difference between at least one pH-sensitive chemical shift of the compound and a pH-independent chemical shift, such pH-independent chemical shift acting as a reference chemical shift, or by measurement of the absolute chemical shift, or by measuring chemical shift differences involving at least one pH-sensitive shift, and
B) an in vivo method for determining pH and/or measuring pH changes comprising the steps of
(i) applying or administering a compound of claim 1 to the body of a human patient or non-human animal, and
(ii) performing magnetic resonance imaging (MRI) and thereby determining one or several pH values or H changes of or in the body of said human patient or non-human animal by obtaining a chemical shift difference between at least one pH-sensitive chemical shift of the compound and a pH-independent chemical shift, such pH-independent chemical shift acting as a reference chemical shift, or by measurement of the absolute chemical shift, or by measuring chemical shift differences involving at least one pH-sensitive chemical shift.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The method according to claim 12, wherein the pH-independent chemical shift (reference chemical shift) is from the compound with at least one pH-sensitive chemical shift, or from another substance, and is used as a pH-independent reference.

### Claim 15 (depends on 1)

A method of diagnosing and/or monitoring treatment of a disease causing changes in pH, comprising the steps of
(i) applying or administering a compound of claim 1 to the body of a human patient or non-human animal,
(ii) performing magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS) and thereby determining several pH values or pH changes of, or in the body of said human patient or non-human animal by obtaining the chemical shift difference between at least one pH sensitive chemical shift of the compound and a pH-independent chemical shift, such pH-independent chemical shift acting as a reference chemical shift, or by measurement of the absolute chemical shift, or by measuring chemical shift difference involving at least one pH-sensitive chemical shift over time, and
(iii) calculating pH maps based on spatially resolved pH values or pH changes determined in the step (ii).

### Claim 16 (depends on 15)

The method according to claim 15, comprising magnetic resonance spectroscopy (MRS) or magnetic resonance tomography (MRT),
and/or wherein the imaging is real-time.

### Claim 17 (depends on 12)

The method according to claim 12, comprising the resolution of a spatial pH distribution,
comprising the use of frequency encoding techniques comprising chemical shift imaging (CSI) and phase sensitive encodings of chemical shifts.

### Claim 18 (depends on 1)

The method of claim 1 used for quality control of food or in the examination of plants and organisms.

### Claim 19 (depends on 4)

The method, according to claim 4, wherein one of R2 and R3 is carboxy.

### Claim 20 (depends on 6)

The method, according to claim 6, wherein the reference compound is a compound that does not exhibit pH-sensitive chemical shift(s) in an NMR spectrum.

### Claim 21 (depends on 12)

The method, according to claim 12, wherein the sample is a cell culture sample, and/or wherein step (iii) is carried out in an MRI scanner machine with MRS or MRSI capabilities or in a NMR spectrometer.

### Claim 22 (depends on 15)

The method, according to claim 15, wherein the disease causing a change in pH is selected from cancers, inflammation, ischemia, renal failure and chronic obstructive pulmonary disease.

### Claim 23 (depends on 15)

The method, according to claim 15, wherein step (iii) comprises comparing said relative chemical shifts to a predetermined calibration curve of the compound with at least one pH-sensitive chemical shift in solutions with known pH.

### Claim 24 (depends on 15)

The method, according to claim 15, wherein said method furthermore comprises hyperpolarizing the compound with at least one pH-sensitive chemical shift before application or administration to the body of the patient.
